{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:01Z","timestamp":1740126121101,"version":"3.37.3"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,23]]},"DOI":"10.1093\/bjd\/ljac033","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:18:26Z","timestamp":1674224306000},"page":"3-3","source":"Crossref","is-referenced-by-count":0,"title":["The promise of personalized medicine for hidradenitis suppurativa"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-7090","authenticated-orcid":false,"given":"Martin M","family":"Okun","sequence":"first","affiliation":[{"name":"Dermatology Department , Fort HealthCare, Fort Atkinson, WI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2023100516253997700_ljac033-B1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bjd\/ljac007","article-title":"B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab","volume":"188","author":"Hambly","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023100516253997700_ljac033-B2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2023100516253997700_ljac033-B3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J Am Acad Dermatol"},{"author":"HUMIRA\u00ae USPI [highlights of prescribing information]","key":"2023100516253997700_ljac033-B4"},{"key":"2023100516253997700_ljac033-B5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","article-title":"CCL28 chemokine: an anchoring point bridging innate and adaptive immunity","volume":"51","author":"Mohan","year":"2017","journal-title":"Int Immunopharmacol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac033\/48085390\/ljac033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/3\/51888159\/ljac033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/3\/51888159\/ljac033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:26:05Z","timestamp":1696523165000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/1\/3\/6819797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2023,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac033","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,11,10]]}}}